Univ Helsinki, Inst Mol Med Finland, HiLIFE, Helsinki, Finland..
Univ Turku, Dept Publ Hlth, Turku, Finland.;Univ Turku, Ctr Populat Hlth Res, Turku, Finland.;Turku Univ Hosp, Turku, Finland..
Univ Turku, Dept Publ Hlth, Turku, Finland.;Univ Skövde, Sch Hlth Sci, Skövde, Sweden..
Univ Helsinki, Clinicum, Fac Med, Helsinki, Finland..
Univ Helsinki, Clinicum, Fac Med, Helsinki, Finland..
Univ Helsinki, Clinicum, Fac Med, Helsinki, Finland..
Finnish Inst Occupat Hlth, Helsinki, Finland..
Finnish Inst Occupat Hlth, Helsinki, Finland..
UCL, Dept Epidemiol & Publ Hlth, London, England..
INSERM, UMS 011, Populat Based Epidemiol Cohorts Unit, Villejuif, France.;Univ Paris, INSERM U1153, Epidemiol Ageing & Neurodegenerat Dis, Paris, France..
INSERM, UMS 011, Populat Based Epidemiol Cohorts Unit, Villejuif, France.;Univ Paris, INSERM U1153, Epidemiol Ageing & Neurodegenerat Dis, Paris, France..
Karolinska Inst, Inst Environm Med, Stockholm, Sweden.;Reg Stockholm, Ctr Occupat & Environm Med, Stockholm, Sweden..
Uppsala Univ, Dept Med Sci, Uppsala, Sweden..
Mid Sweden University, Faculty of Human Sciences, Department of Health Sciences.
Stockholm Univ, Stress Res Inst, Stockholm, Sweden..
Finnish Inst Occupat Hlth, Helsinki, Finland..
Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland..
Univ Helsinki, Clinicum, Fac Med, Helsinki, Finland..
UCL, Dept Epidemiol & Publ Hlth, London, England.;Univ Bristol, Bristol Med Sch, Bristol, Avon, England..
SomaLogic, Boulder, CO USA..
UCL, Div Psychiat, London, England.;Camden & Islington NHS Fdn Trust, London, England..
Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA..
UCL, Dept Epidemiol & Publ Hlth, London, England.;Univ Paris, INSERM U1153, Epidemiol Ageing & Neurodegenerat Dis, Paris, France..
UCL, Dept Neurodegenerat Dis, London, England.;UCL, UK Dementia Res Inst, London, England.;Univ Gothenburg, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Sahlgrenska Acad, Mölndal, Sweden.;Sahlgrens Univ Hosp, Clin Neurochem Lab, Mölndal, Sweden..
UCL, Dept Epidemiol & Publ Hlth, London, England.;Univ Helsinki, Clinicum, Fac Med, Helsinki, Finland..
OBJECTIVES To examine the association between cognitively stimulating work and subsequent risk of dementia and to identify protein pathways for this association. DESIGN Multicohort study with three sets of analyses. SETTING United Kingdom, Europe, and the United States. PARTICIPANTS Three associations were examined: cognitive stimulation and dementia risk in 107 896 participants from seven population based prospective cohort studies from the IPD-Work consortium (individual participant data meta-analysis in working populations); cognitive stimulation and proteins in a random sample of 2261 participants from one cohort study; and proteins and dementia risk in 13 656 participants from two cohort studies. MAIN OUTCOME MEASURES Cognitive stimulation was measured at baseline using standard questionnaire instruments on active versus passive jobs and at baseline and over time using a job exposure matrix indicator. 4953 proteins in plasma samples were scanned. Follow-up of incident dementia varied between 13.7 to 30.1 years depending on the cohort. People with dementia were identified through linked electronic health records and repeated clinical examinations. RESULTS During 1.8 million person years at risk, 1143 people with dementia were recorded. The risk of dementia was found to be lower for participants with high compared with low cognitive stimulation at work (crude incidence of dementia per 10 000 person years 4.8 in the high stimulation group and 7.3 in the low stimulation group, age and sex adjusted hazard ratio 0.77, 95% confidence interval 0.65 to 0.92, heterogeneity in cohort specific estimates I2=0%, P=0.99). This association was robust to additional adjustment for education, risk factors for dementia in adulthood (smoking, heavy alcohol consumption, physical inactivity, job strain, obesity, hypertension, and prevalent diabetes at baseline), and cardiometabolic diseases (diabetes, coronary heart disease, stroke) before dementia diagnosis (fully adjusted hazard ratio 0.82, 95% confidence interval 0.68 to 0.98). The risk of dementia was also observed during the first 10 years of follow-up (hazard ratio 0.60, 95% confidence interval 0.37 to 0.95) and from year 10 onwards (0.79, 0.66 to 0.95) and replicated using a repeated job exposure matrix indicator of cognitive stimulation (hazard ratio per 1 standard deviation increase 0.77, 95% confidence interval 0.69 to 0.86). In analysis controlling for multiple testing, higher cognitive stimulation at work was associated with lower levels of proteins that inhibit central nervous system axonogenesis and synaptogenesis: slit homologue 2 (SLIT2, fully adjusted r3 -0.34, P(0.001), carbohydrate sulfotransferase 12 (CHSTC, fully adjusted r3 -0.33, P(0.001), and peptidyl-glycine alpha-amidating monooxygenase (AMD, fully adjusted r3 -0.32, P(0.001). These proteins were associated with increased dementia risk, with the fully adjusted hazard ratio per 1 SD being 1.16 (95% confidence interval 1.05 to 1.28) for SLIT2, 1.13 (1.00 to 1.27) for CHSTC, and 1.04 (0.97 to 1.13) for AMD. CONCLUSIONS The risk of dementia in old age was found to be lower in people with cognitively stimulating jobs than in those with non-stimulating jobs. The findings that
2021. Vol. 374, article id 374:n1804